Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 06, 2005. The report serves to disclose specific corporate governance updates and changes in directors' interests in compliance with the Financial Services Authority's Listing Rules and the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding personnel and share ownership rather than a financial performance report.
Material Changes
- Board Appointment: Mr. Julian Heslop was appointed to the Board of GlaxoSmithKline plc effective April 1, 2005.
- Share Transactions: On April 05, 2005, the GlaxoSmithKline Employee Trust transferred 1,178 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing details Mr. Heslop's background, noting he has held no directorships of publicly quoted companies in the past five years. It discloses his share interests, including 17,547 Ordinary Shares acquired prior to appointment, 365,719 shares via options, and 25,500 shares under the Performance Share Plan. No specific risks, contingencies, or unusual financial items are discussed in this text.
Investor Verification Points
- Confirm the effective date of Mr. Julian Heslop's board appointment (April 1, 2005).
- Verify the total shareholding and option interests held by Mr. Heslop as disclosed.
- Note that this filing does not contain financial performance data for the period.